A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models

PLoS Neglected Tropical Diseases

Volumn 11, Issue 9, 2017, Pages

  Garrison, Aura R ^a   Shoemaker, Charles J ^a   Golden, Joseph W ^a   Fitzpatrick, Collin J ^a   Suschak, John J ^a   Richards, Michelle J ^a   Badger, Catherine V ^a   Six, Carolyn M ^a   Martin, Jacqueline D ^a   Hannaman, Drew ^b   Zivcec, Marko ^c   Bergeron, Eric ^c   Koehler, Jeffrey W ^a   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Ichor Medical Systems Inc   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; ALPHA BETA INTERFERON RECEPTOR; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CRIMEAN CONGO HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEP-G2 CELL LINE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; SEROCONVERSION; TH1 TH2 BALANCE; VACCINATION; VACCINE IMMUNOGENICITY; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BLOOD; DEFICIENCY; DISEASE MODEL; GENETICS; HEMORRHAGIC FEVER, CRIMEAN; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; MOUSE; NAIROVIRUS; TH1 CELL; TH2 CELL; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNITY, HUMORAL; IMMUNOCOMPROMISED HOST; IMMUNOGENICITY, VACCINE; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, DNA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 85030640288     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005908     Document Type: Article

References (40)

1. Flick R, Whitehouse CA, Crimean-Congo hemorrhagic fever virus. Current molecular medicine. 2005;5(8):753–60. 16375710.
2. Schmaljohn CS, Nichol ST, KDaH PM, Bunyaviridae. In: Fields Virology. 5th edn. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1741–89.
3. Shepherd AJ, Leman PA, Swanepoel R, Viremia and antibody response of small African and laboratory animals to Crimean-Congo hemorrhagic fever virus infection. The American journal of tropical medicine and hygiene. 1989;40(5):541–7. 2499205.
4. Spengler JR, Bergeron E, Rollin PE, Seroepidemiological Studies of Crimean-Congo Hemorrhagic Fever Virus in Domestic and Wild Animals. PLoS neglected tropical diseases. 2016;10(1):e0004210. doi: 10.1371/journal.pntd.0004210 26741652.
5. Mertens M, Schmidt K, Ozkul A, Groschup MH, The impact of Crimean-Congo hemorrhagic fever virus on public health. Antiviral research. 2013;98(2):248–60. doi: 10.1016/j.antiviral.2013.02.007 23458713.
6. Conger NG, Paolino KM, Osborn EC, Rusnak JM, Gunther S, Pool J, et al. Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerging infectious diseases. 2015;21(1):23–31. doi: 10.3201/eid2101.141413 25529825.
7. Smego RA, Jr.Sarwari AR, Siddiqui AR, Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis. 2004;38(12):1731–5. doi: 10.1086/421093 15227619.
8. Leblebicioglu H, Ozaras R, Irmak H, Sencan I, Crimean-Congo hemorrhagic fever in Turkey: Current status and future challenges. Antiviral research. 2016;126:21–34. doi: 10.1016/j.antiviral.2015.12.003 26695860.
9. Ince Y, Yasa C, Metin M, Sonmez M, Meram E, Benkli B, et al. Crimean-Congo hemorrhagic fever infections reported by ProMED. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2014;26:44–6. doi: 10.1016/j.ijid.2014.04.005 24947424.
10. Messina JP, Pigott DM, Duda KA, Brownstein JS, Myers MF, George DB, et al. A global compendium of human Crimean-Congo haemorrhagic fever virus occurrence. Sci Data. 2015;2:150016. doi: 10.1038/sdata.2015.16 25977820.
11. Estrada-Pena A, Palomar AM, Santibanez P, Sanchez N, Habela MA, Portillo A, et al. Crimean-Congo hemorrhagic fever virus in ticks, Southwestern Europe, 2010. Emerging infectious diseases. 2012;18(1):179–80. doi: 10.3201/eid1801.111040 22261502.
12. Garcia Rada A, First outbreak of Crimean-Congo haemorrhagic fever in western Europe kills one man in Spain. Bmj. 2016;354:i4891. doi: 10.1136/bmj.i4891 27609364.
13. Papa A, Papadimitriou E, Christova I, The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis. 2010;43(3):225–9. Epub 2010/12/15. doi: 10.3109/00365548.2010.540036 21142621.
14. Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A, Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine. 2012;30(44):6225–9. doi: 10.1016/j.vaccine.2012.08.003 22902680.
15. Bente DA, Alimonti JB, Shieh WJ, Camus G, Stroher U, Zaki S, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol. 2010;84(21):11089–100. Epub 2010/08/27. doi: 10.1128/JVI.01383-10 20739514.
16. Zivcec M, Safronetz D, Scott D, Robertson S, Ebihara H, Feldmann H, Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. The Journal of infectious diseases. 2013;207(12):1909–21. doi: 10.1093/infdis/jit061 23417661.
17. Bereczky S, Lindegren G, Karlberg H, Akerstrom S, Klingstrom J, Mirazimi A, Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol. 2010;91(Pt 6):1473–7. Epub 2010/02/19. doi: 10.1099/vir.0.019034-0 20164263.
18. Akira S, Functional roles of STAT family proteins: lessons from knockout mice. Stem cells. 1999;17(3):138–46. doi: 10.1002/stem.170138 10342556.
19. Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, et al. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice. Vector borne and zoonotic diseases. 2015;15(12):759–64. doi: 10.1089/vbz.2015.1855 26684523.
20. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PLoS One. 2014;9(3):e91516. doi: 10.1371/journal.pone.0091516 24621656.
21. Canakoglu N, Berber E, Tonbak S, Ertek M, Sozdutmaz I, Aktas M, et al. Immunization of knock-out alpha/beta interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS neglected tropical diseases. 2015;9(3):e0003579. doi: 10.1371/journal.pntd.0003579 25760444.
22. Dowall SD, Graham VA, Rayner E, Hunter L, Watson R, Taylor I, et al. Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses. PloS one. 2016;11(6):e0156637. doi: 10.1371/journal.pone.0156637 27272940.
23. Hinkula J, Devignot S, Akerstrom S, Karlberg H, Wattrang E, Bereczky S, et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J Virol. 2017. doi: 10.1128/JVI.02076-16 28250124.
24. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C, Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine. 2006;24(21):4657–66. Epub 2005/09/22. doi: 10.1016/j.vaccine.2005.08.034 16174542.
25. Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, et al. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS pathogens. 2011;7(12):e1002407. doi: 10.1371/journal.ppat.1002407 22144897.
26. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207–11. doi: 10.1126/science.1235214 23580529.
27. Smith DR, Hollidge B, Daye S, Zeng X, Blancett C, Kuszpit K, et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS neglected tropical diseases. 2017;11(1):e0005296. doi: 10.1371/journal.pntd.0005296 28068342.
28. Council NR, Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, D.C.: National Academies Press; 2011.
29. Altamura LA, Bertolotti-Ciarlet A, Teigler J, Paragas J, Schmaljohn CS, Doms RW, Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol. 2007;81(12):6632–42. doi: 10.1128/JVI.02730-06 17409136.
30. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, et al. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clinical and vaccine immunology: CVI. 2011;18(5):707–16. doi: 10.1128/CVI.00030-11 21450977.
31. Zivcec M, Metcalfe MG, Albarino CG, Guerrero LW, Pegan SD, Spiropoulou CF, et al. Assessment of Inhibitors of Pathogenic Crimean-Congo Hemorrhagic Fever Virus Strains Using Virus-Like Particles. PLoS neglected tropical diseases. 2015;9(12):e0004259. doi: 10.1371/journal.pntd.0004259 26625182.
32. Lindenbach BD, Measuring HCV infectivity produced in cell culture and in vivo. Methods in molecular biology. 2009;510:329–36. doi: 10.1007/978-1-59745-394-3_24 19009272.
33. Kwilas S, Kishimori JM, Josleyn M, Jerke K, Ballantyne J, Royals M, et al. A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Current gene therapy. 2014;14(3):200–10. doi: 10.2174/1566523214666140522122633 24867065.
34. Saijo M, Qing T, Niikura M, Maeda A, Ikegami T, Prehaud C, et al. Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Clin Microbiol. 2002;40(5):1587–91. doi: 10.1128/JCM.40.5.1587-1591.2002 11980926.
35. Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J, Altamura LA, McFalls JM, et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol. 2005;79(10):6152–61. Epub 2005/04/29. doi: 10.1128/JVI.79.10.6152-6161.2005 15858000.
36. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161(4):1947–53. 9712065.
37. Gallucci S, Lolkema M, Matzinger P, Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5(11):1249–55. doi: 10.1038/15200 10545990.
38. Braun D, Caramalho I, Demengeot J, IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol. 2002;14(4):411–9. 11934877.
39. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008;451(7179):725–9. doi: 10.1038/nature06537 18256672.
40. Suschak JJ, Wang S, Fitzgerald KA, Lu S, A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol. 2016;196(1):310–6. doi: 10.4049/jimmunol.1501836 26590319.